Regulatory News:
SpineGuard (FR0011464452 ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, publishes on its Annual Shareholders' Meeting held on Wednesday June 26, 2024, convened on the second notice at the offices of the law firm Ashurst Paris, located at 18 square Edouard VII, 75009 Paris.
The shareholders present or represented were holding 10,792,256 shares, representing a quorum of 22.75%.
All the resolutions of this Annual Shareholders' Meeting were adopted with the exception of the 22nd resolution, as recommended by the Board of Directors.
To close the Annual Shareholders' Meeting,Pierre Jérôme, Chairman, CEO and Co-founder of SpineGuard, thanked all the shareholders for their votes.
The minutes of the Annual Shareholders' Meeting will be available within the legal deadlines on SpineGuard's website: www.spineguard.com, in the "Investors/Shareholders Meeting" section.
Upcoming financial event:
H1 2024 revenue, on July 15, 2024, after market
About SpineGuard®
Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices embedding its technology. Over 100,000 surgical procedures have been secured worldwide thanks to DSG® and 34 studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard is expanding the scope of its DSG® technology to the treatment of scoliosis via anterior approach, sacroiliac joint fusion, dental implantology and innovations such as the smart pedicle screw and power drill or surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives.
For further information, visit www.spineguard.com
Disclaimer
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626217857/en/
Contacts:
SpineGuard
Pierre Jérôme
CEO Chairman
Tel.: +33 1 45 18 45 19
p.jerome@spineguard.com
SpineGuard
Anne-Charlotte Millard
CFO
Tel.: +33 1 45 18 45 19
ac.millard@spineguard.com
NewCap
Investor Relations Financial Communication
Mathilde Bohin Aurélie Manavarere
Tel.: +33 1 44 71 94 94
spineguard@newcap.eu
